CSIMarket
 


Plx Pharma Inc   (PLXP)
Other Ticker:  
 

Plx Pharma Inc 's Leverage Ratio

PLXP's quarterly Leverage Ratio and Total Liabilities, Equity growth


In Spite of the repayements of liabilities of -21.68%, in III Quarter 2022 ,Leverage Ratio deteriorated to 1.91 is above the company's typical Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the third quarter 2022, 380 other companies have achieved lower Leverage Ratio than Plx Pharma Inc in the III Quarter 2022. While Leverage Ratio total ranking has deteriorated compared to the second quarter 2022 from 2567 to 2627 .

Explain Leverage Ratio?
Who are PLXP Customers?
What are PLXP´s Total Liabilities?


PLXP Leverage Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Equity Change -67.03 % -58.89 % -41.85 % - -
Y / Y Total Liabilities Change -66.2 % -41.09 % -1.57 % 44.63 % 158.09 %
Leverage Ratio MRQ 1.91 1.51 1.23 1.05 1.87
PLXP's Total Ranking # 2627 # 2567 # 2606 # 1313 # 2798
Seq. Equity Change -38.23 % -36.5 % -27.19 % 15.45 % -22.99 %
Seq. Total Liabilities Change -21.68 % -22.38 % -14.23 % -35.18 % 36.52 %



Leverage Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 381
Healthcare Sector # 790
Overall Market # 2627


Leverage Ratio Statistics
High Average Low
5.23 1.09 0.02
(Dec 31 2017)   (Mar 31 2014)




Financial Statements
Plx Pharma Inc 's Equity $ 10 Millions Visit PLXP's Balance sheet
Plx Pharma Inc 's Total Liabilities $ 19 Millions Visit PLXP's Balance sheet
Source of PLXP's Sales Visit PLXP's Sales by Geography


Cumulative Plx Pharma Inc 's Leverage Ratio

PLXP's Leverage Ratio for the trailling 12 Months

PLXP Leverage Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Equity TTM Growth -67.03 % -58.89 % -41.85 % - -
Y / Y Total Liabilities TTM Growth -66.2 % -41.09 % -1.57 % 44.63 % 158.09 %
Leverage Ratio TTM 1.29 1.39 1.28 1.12 1.51
Total Ranking TTM # 18 # 2498 # 17 # 2506 # 21
Seq. Equity TTM Growth -38.23 % -36.5 % -27.19 % 15.45 % -22.99 %
Seq. Total Liabilities TTM Growth -21.68 % -22.38 % -14.23 % -35.18 % 36.52 %


On the trailing twelve months basis Due to repayements of liabilities of -21.68% Plx Pharma Inc decreased Leverage Ratio in the 12 months ending in III Quarter 2022 to 1.29, below the company's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry PLXP recorded the lowest Leverage Ratio. While Leverage Ratio total ranking has improved so far to 18, from total ranking in previous 12 month period at 2498.

Explain Leverage Ratio?
Who are PLXP Customers?
What are PLXP´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 1
Healthcare Sector # 2
Within the Market # 18


trailing twelve months Leverage Ratio Statistics
High Average Low
6.61 2.22 0.79
(Mar 31 2019)   (Sep 30 2017)




Companies with similar Leverage Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Leverage RatioSep 30 2022 MRQ Total LiabilitiesSep 30 2022 MRQ Equity
Collegium Pharmaceutical Inc   5.05 $ 996.399  Millions$ 197.194  Millions
Adc Therapeutics Sa  4.96 $ 440.441  Millions$ 88.727  Millions
Applied Therapeutics inc   4.83 $ 46.514  Millions$ 9.629  Millions
Gossamer Bio Inc   4.74 $ 267.187  Millions$ 56.351  Millions
Amicus Therapeutics inc   4.73 $ 626.963  Millions$ 132.565  Millions
China Pharma Holdings Inc   4.72 $ 13.369  Millions$ 2.835  Millions
Intercept Pharmaceuticals inc   4.20 $ 451.728  Millions$ 107.676  Millions
Xeris Biopharma Holdings Inc   4.02 $ 221.379  Millions$ 55.040  Millions
Seelos Therapeutics inc   4.01 $ 31.629  Millions$ 7.879  Millions
Bellicum Pharmaceuticals Inc   3.94 $ 29.532  Millions$ 7.499  Millions
Revance Therapeutics Inc   3.88 $ 565.878  Millions$ 145.713  Millions
Mei Pharma Inc   3.38 $ 126.275  Millions$ 37.308  Millions
Societal Cdmo Inc   3.26 $ 114.970  Millions$ 35.234  Millions
Neptune Wellness Solutions Inc   3.17 $ 49.417  Millions$ 15.596  Millions
Ascendis Pharma A  3.14 $ 925.557  Millions$ 294.950  Millions
Teva Pharmaceutical Industries Limited  3.13 $ 29,796.000  Millions$ 9,519.000  Millions
Journey Medical Corporation  3.08 $ 80.587  Millions$ 26.184  Millions
Dmk Pharmaceuticals Corporation  2.97 $ 8.452  Millions$ 2.845  Millions
Biovie Inc   2.82 $ 16.821  Millions$ 5.961  Millions
Eli Lilly And Company  2.64 $ 26,798.200  Millions$ 10,165.900  Millions
G1 Therapeutics Inc   2.62 $ 120.608  Millions$ 45.965  Millions
Fortress Biotech Inc   2.58 $ 261.890  Millions$ 101.352  Millions
Seres Therapeutics Inc   2.56 $ 172.913  Millions$ 67.585  Millions
Aveo Pharmaceuticals Inc   2.51 $ 72.388  Millions$ 28.845  Millions
Mersana Therapeutics Inc   2.49 $ 224.621  Millions$ 90.229  Millions
Celyad Oncology Sa  2.47 $ 11.966  Millions$ 4.835  Millions
Ultragenyx Pharmaceutical Inc   2.42 $ 1,134.868  Millions$ 468.829  Millions
Mallinckrodt Plc  2.38 $ 4,408.300  Millions$ 1,849.100  Millions
Jazz Pharmaceuticals Plc  2.37 $ 6,508.768  Millions$ 2,745.194  Millions
Rockwell Medical inc   2.36 $ 38.050  Millions$ 16.136  Millions

Date modified: 2023-03-25T14:07:09+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com